Announcements and Notices - [Other - Business Update]

Ocumension Therapeutics operates as a pharmaceutical company. The Company focuses on identifying, developing, and commercializing ophthalmic therapies. Ocumension Therapeutics serves customers in the United States and China.

Voluntary Announcement Approval Received For Marketing Ot-702 In China

Financial Statements/ESG Information - [Interim/Half-Year Report]

2025 Interim Report

Voluntary Announcement
Primary Endpoint Achieved In The Second
Phase Iii Clinical Trial Of Ot-301

Announcements and Notices - [Interim Results]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ocumension Therapeutics (1477 HK)

Voluntary Announcement Approval Received For Marketing Ot-702 In China

2025 Interim Report

Voluntary Announcement Primary Endpoint Achieved In The Second Phase Iii Clinical Trial Of Ot-301

Interim Results Announcement For The Six Months Ended June 30, 2025

Next Day Disclosure Return

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)